Pheon Therapeutics Launches with $68M Series A

Funding Rounds

▤ Summary

BOSTON, MA, Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist, launched following the closing of a $68 million Series A financing. Pheon Therapeutics (Pheon), an Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched following the closing of a $68 million Series A financing in March 2022. The financing was led by Brandon Capital, Forbion and Atlas Venture, with participation from seed investor Research Corporation Technologies (RCT). (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

$ Funding

$
Amount - Total raised
□
Date - Announcement date
◎
Investors Video Island Lead investors
▥
Company - Funded company

▥ Classifications

industries
Fintech & Banking
applications
Accounting and Taxes

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies